8-K: Minerva Secures $200M for Schizophrenia Drug Trial

Minerva Neurosciences announced a private placement of up to $200 million to fund its Phase 3 confirmatory trial for roluperidone in schizophrenia and prepare for NDA resubmission and commercial launch.

Summary

• Minerva Neurosciences entered into a securities purchase agreement for a private placement of up to $200 million in gross proceeds.
• The financing includes an initial upfront funding of $80 million in exchange for shares of Series A Convertible Preferred Stock.
• Up to an additional $80 million may be received from the exercise of Tranche A warrants, which are immediately exercisable for cash until 10 days after the Phase 3 trial's primary endpoint milestone.
• A further $40 million may be received from the exercise of Tranche B warrants, exercisable upon the earlier of the Phase 3 milestone event or three years from issuance, and expiring on the four-year anniversary of issuance.
• Net proceeds will finance the confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, including upsizing the trial, preparation and resubmission of its New Drug Application (NDA), and readiness for commercial launch in the U.S., if approved.
• The FDA has aligned on the Phase 3 trial design, which will evaluate a 64 mg dose of roluperidone in a 1:1 randomized double-blind, placebo-controlled study, with the primary endpoint being the change from Baseline in PANSS Marder negative symptoms factor score (NSFS) at 12 weeks.
• Stockholder approval is required for the conversion of Series A Preferred Stock into Common Stock.
• Investors in the private placement have the right to appoint up to three additional directors with significant schizophrenia clinical trial experience to the board.
• A Scientific Advisory Board (SAB) will be constituted, with members mutually agreed upon by the Company and Vivo Capital LLC, to advise on the Phase 3 trial.

Sentiment

Score: 8

Explanation: The significant capital raise and clear FDA alignment for the Phase 3 trial of roluperidone for an unmet medical need in schizophrenia represent a strong positive development, substantially de-risking the drug's path to market.

Positives

• Secured significant funding of up to $200 million, providing substantial capital for key development milestones.
• Achieved alignment with the FDA on the design of the confirmatory Phase 3 trial for roluperidone, providing a clear regulatory path forward.
• Funding is expected to cover the Phase 3 trial, NDA resubmission, and commercial launch preparations, reducing near-term financial uncertainty.
• The appointment of up to three directors with significant schizophrenia clinical trial experience will strengthen the board's expertise.
• The establishment of a Scientific Advisory Board (SAB) will provide expert oversight and support for the pivotal Phase 3 trial.
• Roluperidone targets negative symptoms of schizophrenia, an area acknowledged by the FDA as an unmet medical need.

Negatives

• Conversion of Series A Preferred Stock into Common Stock is contingent on stockholder approval, which introduces a potential delay or hurdle.
• Tranche B warrants are subject to forfeiture if the investor sells or transfers Series A Preferred Stock or converted Common Stock before the exercisability date (with exceptions for affiliates).
• All warrants are subject to forfeiture if the holder engages in Short Sales of the company's securities during the 48-month period following the Closing Date.
• If stockholder approval for conversion is not obtained within one year, Series A Preferred Stock holders have a redemption right at twice the original per share price plus unpaid dividends, which could result in a significant cash outflow for the company.

Risks

• Forward-looking statements may differ materially from actual results due to various factors.
• Future financial performance and position may not improve, potentially hindering the implementation of the business strategy.
• Existing cash resources and runway may prove inaccurate, necessitating additional financing sooner than anticipated or leading to unexpected liquidity constraints.
• Internal and external costs for ongoing and planned activities may exceed expectations, accelerating cash burn or requiring changes/curtailment of plans.
• Clinical trials and studies may be delayed, may not yield satisfactory outcomes, and earlier trial results may not be predictive of later trials.
• The design and enrollment rate for clinical trials, including the Phase 3 confirmatory trial, may not enable successful completion.
• The commercial opportunity for roluperidone in negative symptoms of schizophrenia may be smaller than projected.
• Inability to obtain and maintain necessary regulatory approvals.
• Uncertainties inherent in the initiation and completion of clinical trials and clinical development.
• The need to align with collaborators or partners may hamper or delay development and regulatory efforts or increase costs.
• Uncertainties related to patent protection and potential litigation.
• General economic conditions could adversely impact the company's operations and financial results.
• Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

Minerva Neurosciences expects to be sufficiently funded through the confirmatory Phase 3 trial for roluperidone, its New Drug Application (NDA) resubmission to the FDA, and preparation for commercial launch in the U.S., if approved. The company plans to refocus all efforts on the successful execution of the Phase 3 trial with the objective of demonstrating roluperidone's efficacy in treating negative symptoms of schizophrenia.

Management Comments

• "We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms."
• "I would like to thank the FDA for their engagement in defining a path forward for roluperidones development. Their guidance and advice, including the FDA Public Meeting in August 2024 has been invaluable."
• "I would also like to thank our investors for their confidence in our ability to advance roluperidone and for providing the financial resources necessary to enable Minerva to conduct the confirmatory Phase 3 trial and, if successful make roluperidone available to millions of patients worldwide."

Industry Context

Schizophrenia is a widespread and debilitating psychiatric disorder with significant health, social, and economic burdens. While existing antipsychotics effectively reduce positive symptoms like delusions and hallucinations, they do not address primary negative symptoms (e.g., blunted affect, avolition, anhedonia), which are extremely debilitating and prevent independent living. The FDA has acknowledged that there is currently an unmet medical need for treatments specifically targeting these negative symptoms. Minerva's roluperidone aims to fill this critical gap in the schizophrenia treatment landscape.

Comparison to Industry Standards

• The FDA acknowledges that no currently approved antipsychotics specifically treat negative symptoms of schizophrenia, highlighting roluperidone's potential to address a significant unmet medical need in the industry.
• The agreed-upon Phase 3 trial design, including a 64 mg dose, 1:1 randomized double-blind, placebo-controlled study, and the PANSS Marder negative symptoms factor score (NSFS) as the primary endpoint at 12 weeks, aligns with current regulatory expectations for demonstrating efficacy in this indication.
• The requirement for observational assessment of positive symptom relapses for at least 52 weeks in monotherapy patients is a specific regulatory standard for drugs seeking a monotherapy indication in schizophrenia, ensuring comprehensive safety and efficacy evaluation.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Existing common shareholders face potential dilution from the future conversion of Series A Preferred Stock and warrants into Common Stock. However, the financing provides critical capital to advance roluperidone, which, if successful, could significantly increase long-term shareholder value. Stockholder approval for conversion provides a mechanism for existing shareholders to vote on this dilution.
• **Investors (Purchasers)**: These institutional investors provide substantial capital and receive Series A Preferred Stock and warrants, gaining significant exposure to the company's future success. They also secure board representation and protective provisions (e.g., liquidation preference, consent rights) until stockholder approval. They are subject to forfeiture clauses for short sales or early transfers of Tranche B warrant shares.
• **Employees**: The financing secures the company's ability to continue operations and advance its lead drug candidate, providing stability and potential for future growth and success.
• **Patients**: The funding and FDA alignment offer a clearer path for the development of roluperidone, potentially leading to a new therapeutic option for negative symptoms of schizophrenia, an area with significant unmet medical need.

Next Steps

• The closing of the private placement is expected to occur on or about October 23, 2025.
• File a preliminary proxy statement for stockholder approval of proposals within 45 days following the Issuance Date.
• File and mail a definitive proxy statement as soon as practicable after SEC review.
• Obtain stockholder approval for the issuance of Common Stock upon conversion of Series A Preferred Stock and warrants.
• Increase the size of the Board of Directors and appoint up to three directors designated by Vivo Capital LLC as soon as practicable following the Closing.
• Constitute a Scientific Advisory Board (SAB) with members mutually agreed upon by the Company and Vivo Capital LLC.
• Conduct the confirmatory Phase 3 clinical trial of roluperidone in schizophrenia.
• Prepare and resubmit the New Drug Application (NDA) to the FDA.
• Prepare for the commercial launch of roluperidone in the U.S., if approved.
• File a registration statement on Form S-3 for the resale of Common Stock issuable upon conversion of the Series A Preferred Stock and warrants within 15 days following Stockholder Approval.

Key Dates

Recommendation

The substantial capital infusion of up to $200 million, coupled with clear FDA alignment on the Phase 3 trial design for roluperidone, significantly de-risks Minerva Neurosciences' development pathway for a drug targeting a major unmet medical need in schizophrenia. The funding is explicitly allocated to critical milestones including trial upsizing, NDA resubmission, and commercial launch preparations, providing a clear runway. The addition of experienced directors and a Scientific Advisory Board further strengthens governance and clinical execution. While stockholder approval for conversion is a near-term hurdle, the overall strategic and financial positioning is highly favorable for long-term value creation, warranting a strong buy recommendation for investors with a higher risk tolerance in the biopharmaceutical sector.

Keywords

Minerva Neurosciences, NERV, Schizophrenia, Roluperidone, Phase 3 trial, Negative Symptoms, Private Placement, Series A Preferred Stock, Warrants, NDA resubmission, Biopharmaceutical, Clinical-stage, Drug development, FDA alignment, Capital raise, Vivo Capital